Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare

Area of Science:

• Rheumatology
• Immunology
• Vascular Medicine

Background:

• Polyarteritis nodosa (PAN) is a systemic vasculitis often requiring immunosuppression with glucocorticoids and cyclophosphamide.
• Severe or refractory PAN cases are linked to significant complications, including accelerated atherosclerosis.
• Accelerated atherosclerosis in refractory PAN can lead to critical ischemic events.

Observation:

• A case report details a 71-year-old male with PAN refractory to glucocorticoids and cyclophosphamide.
• The patient experienced relapsing systemic vasculitis and subsequent accelerated atherosclerosis.
• Severe ischemic lesions necessitated lower limb amputation.

Findings:

• Treatment with rituximab induced remission in this refractory PAN case.
• Biological inflammation markers resolved following rituximab administration.
• Regression of ischemic lesions in the upper limbs was observed.

Implications:

• A systematic vascular evaluation is recommended for patients with refractory vasculitis.
• Further therapeutic trials are necessary to establish the efficacy and optimal role of rituximab in PAN treatment.